Drug news
Early results from Phase II study of Gammagard Liquid 10%(Baxter) for Alzheimers Disease
Baxter International presented three-year data on 16 patients in the Phase II study of Gammagard, which originally enrolled 24 participants. Overall, all 11 study participants who received Gammagard for the full three years showed improvements in thinking abilities, behavior and daily functioning.Of these, the four patients who received the most effective dose (0.4g/kg) for the full 36 months fared the best, showing no decline on several standard measures of cognition, memory, daily functioning and mood. The real proof of Gammagard's effectiveness will come early next year with the release of results of the large-scale, Phase II study.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins